Dupilumab (DUP) is the first biological agent used treating atopic dermatitis (AD). Notwithstanding its high cost, the type of patient group for which the drug is effective remains unclear. In this retrospective study, we aimed to identify novel and reliable biomarkers which can be measured before DUP administration and to predict the efficacy of DUP. Serum samples from 19 patients with AD treated with DUP were analysed by metabolome analysis using gas chromatography–mass spectrometry. Total 148 metabolites were detected, and the relative values of the metabolites were compared between the patient group that achieved 75% improvement in Eczema Area and Severity Index 16 weeks after administration of DUP (high responders: HR; n = 11) and that did not (low responders: LR; n = 8). The HR and LR groups had significant differences in the relative values of the eight metabolites (lactic acid, alanine, glyceric acid, fumaric acid, nonanoic acid, ribose, sorbitol, and ornithine), with ribose emerging as the best. Furthermore, we evaluated the serum concentrations of ribose and found that ribose may be a useful metabolite biomarker for predicting the efficacy of DUP in AD.

中文翻译：

---

探索代谢生物标志物来预测 Dupilumab 治疗特应性皮炎的疗效

Dupilumab (DUP) 是第一个用于治疗特应性皮炎 (AD) 的生物制剂。尽管成本高昂，但该药物对哪些患者群体有效仍不清楚。在这项回顾性研究中，我们的目的是确定可以在 DUP 给药前测量的新颖且可靠的生物标志物，并预测 DUP 的疗效。使用气相色谱-质谱法通过代谢组分析对 19 名接受 DUP 治疗的 AD 患者的血清样本进行了分析。共检测到 148 种代谢物，并比较给予 DUP 16 周后湿疹面积和严重指数改善 75% 的患者组（高反应者：HR； n  = 11）与未改善的患者组之间代谢物的相对值。（低响应者：LR；n  = 8）。HR组和LR组8种代谢物（乳酸、丙氨酸、甘油酸、富马酸、壬酸、核糖、山梨醇、鸟氨酸）的相对值存在显着差异，其中核糖表现最好。此外，我们评估了核糖的血清浓度，发现核糖可能是预测 DUP 在 AD 中的疗效的有用代谢生物标志物。